ACTOPLUS MET XR Drug Patent Profile

Which patents cover Actoplus Met Xr, and when can generic versions of Actoplus Met Xr launch?

Actoplus Met Xr is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-two patent family members in twenty-five countries.

The generic ingredient in ACTOPLUS MET XR is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Actoplus Met Xr

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ACTOPLUS MET XR

International Patents:	72
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	4
Drug Prices:	Drug price information for ACTOPLUS MET XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACTOPLUS MET XR
DailyMed Link:	ACTOPLUS MET XR at DailyMed

See drug prices for ACTOPLUS MET XR

Recent Clinical Trials for ACTOPLUS MET XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Fourth Affiliated Hospital of Zhejiang University School of Medicine	PHASE4
National Cancer Institute (NCI)	Phase 2
Torrent Pharmaceuticals Limited	Phase 1

See all ACTOPLUS MET XR clinical trials

Paragraph IV (Patent) Challenges for ACTOPLUS MET XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ACTOPLUS MET XR	Extended-release Tablets	metformin hydrochloride; pioglitazone hydrochloride	15 mg/1000 mg and 30 mg/1000 mg	022024	1	2011-09-23

US Patents and Regulatory Information for ACTOPLUS MET XR

ACTOPLUS MET XR is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No			Y

Expired US Patents for ACTOPLUS MET XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009

International Patents for ACTOPLUS MET XR

See the table below for patents covering ACTOPLUS MET XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	240698	PROCEDIMIENTO PARA PREPARAR COMPUESTOS DE 5-(4-(2-(5-ETIL-2-PIRIDIL)-ETOXI)BENZIL)-2,4-TIAZOLIDINDIONA Y SUS SALES (PROCESS FOR THE PREPARATION OF 5-(4-(2-(5-ETHYL-2-PYRIDIL)-ETHOXY)BENZYL)-2,4-THIAZOLODINEDIONE AND THEIR SALTS)
Austria	41931
Australia	5246786
Australia	572719
Brazil	1100325
Canada	1277323	DERIVES DE THIAZOLIDINEDIONE, LEUR PRODUCTION ET LEUR EMPLOI (THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE)

Supplementary Protection Certificates for ACTOPLUS MET XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0861666	91298	Luxembourg		91298, EXPIRES: 20210620
0861666	300258	Netherlands		300258, 20160620, EXPIRES: 20210619
0861666	SPC 038/2006	Ireland		SPC 038/2006: 20070528, EXPIRES: 20210619
0861666	07C0006	France		PRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
0861666	CA 2007 00001	Denmark
0861666	SPC/GB07/009	United Kingdom		SPC/GB07/009: 20070126

Actoplus Met XR market dynamics and financial trajectory (revenue exposure, competition, and exclusivity-driven risk)

Last updated: July 2, 2026

Actoplus Met XR (metformin HCl + pioglitazone HCl extended-release) sits in the fixed-dose, oral type 2 diabetes (T2D) market where pricing pressure and channel mix matter more than clinical differentiation. The financial trajectory is typically constrained by (i) patent/indication exclusivity timelines tied to metformin and pioglitazone combinations, (ii) rapid generic availability risk for fixed-dose combinations, (iii) aggressive payer formulary management against higher-priced GLP-1– and SGLT2-led regimens, and (iv) competitive substitution toward cheaper branded alternatives and generics of the individual components.

No complete, publication-quality financial trajectory (revenue figures by year, segment contribution, and current sales trend) can be stated here because no drug-specific audited or consistently sourced sales dataset is provided in the input.

---

How is Actoplus Met XR priced and reimbursed in the U.S. T2D market?

Market structure. Fixed-dose oral diabetes combinations compete on net price after rebates. Payers often prefer least-cost alternatives within tiers that include (a) metformin generics, (b) pioglitazone generics, and (c) other combination regimens with favorable rebate positions.

Key pricing dynamics shaping net sales.

• Wholesale acquisition cost vs net price. Actoplus Met XR’s list pricing is only part of the story; rebate pressure from large pharmacy benefit managers typically compresses net realization over time, especially after generic encroachment.
• Formulary tiering. If Actoplus Met XR is not a “preferred” brand in major formularies, utilization migrates to lower-copay options, usually metformin + pioglitazone as separate products or lower-priced combination equivalents.
• Step therapy. Even when a fixed-dose combination is covered, plans frequently use step edits requiring trials of individual generics before authorizing a brand combination.

Commercial implication. In T2D, the “win” is often payer access rather than prescriber preference. For Actoplus Met XR, the market tends to be loss-making relative to competitors whenever rebate leverage is weak and generic substitution is available at the component level.

---

What share of Actoplus Met XR revenue is exposed to generic substitution risk?

Primary risk vector. Fixed-dose combinations of off-patent drugs face higher generic substitution velocity than single-molecule branded products. When the active ingredients are available generically, the fixed-dose can be vulnerable if formulation or extended-release positioning does not create strong exclusivity barriers.

Where revenue exposure concentrates.

• Tighter formulary categories. Plans more readily swap fixed-dose brands for generic metformin + pioglitazone. If Actoplus Met XR is not structurally protected, utilization can shift quickly when competing products gain approval and launch.
• Pharmacy-level switching. Where biosimilar-style switching rules do not apply, generic substitution still occurs under standard pharmacy benefit dynamics.
• Specialty/340B dynamics. If the product is used in settings with different rebate structures, sales may remain higher than forecast even after exclusivity gaps, but sustained growth remains unlikely.

Commercial implication. Expect sales growth to plateau early and drift downward when generic equivalents of the fixed-dose or close substitutes reach meaningful market share.

---

When does Actoplus Met XR lose exclusivity, and how does that timeline drive financial trajectory?

Exclusivity-driven pattern in T2D combination products.

• The financial trajectory usually shows three phases: (1) launch and early access building, (2) plateau while branded demand is supported by formulary placement and limited competition, (3) decline after relevant patent or regulatory barriers clear and generic entry expands.

What typically determines the start of decline.

• Patent expiry for fixed-dose formulation and extended-release technology
• Orange Book-listed method-of-use or formulation claims
• Any secondary patent family that blocks generic approval
• Settlement or “authorized generic” arrangements, if they exist

Important constraint for this analysis. The specific patent/Orange Book dates for Actoplus Met XR are not included in the user input, so no exact expiration calendar can be provided.

---

What is the Orange Book status of Actoplus Met XR, and which patent listings matter for generics?

Orange Book categories that drive generic launch timing.

• Drug substance patents (metformin/pioglitazone-related claim coverage)
• Drug product patents (extended-release tablet formulation, coatings, matrix systems)
• Method-of-use patents (T2D dosing regimens, titration, specific patient subsets)
• Manufacturing process patents (less common but can be relevant)

What matters commercially.

• If Orange Book listings are dominated by product/formulation patents with limited enforceability, generic entry can occur with design-around.
• If method-of-use patents exist and enforcement is active, launch may be delayed or contested via Paragraph IV.

Important constraint for this analysis. No Orange Book listing data (patent numbers, expiration dates, claim types, or certifications) is provided in the input, so the status cannot be stated.

---

How many patents protect the combination of metformin + pioglitazone extended-release, and how strong is the estate?

Patent estate “strength” factors for fixed-dose generics.

• Claim breadth across extended-release mechanisms and dosage forms
• Likelihood of design-around for excipients, matrix characteristics, or release profiles
• Patent family longevity (original + continuation filings)
• Litigation history (validity/enforceability track record)
• Settlement posture of brand and generic challengers

Important constraint for this analysis. The dataset of Actoplus Met XR patents is not included, so the number of patents and strength ranking cannot be calculated.

---

Which companies are challenging Actoplus Met XR with Paragraph IV filings?

Paragraph IV challenges typically become visible once ANDA litigation is filed in federal court. These events often precede:

• a discrete step-down in sales expectations,
• increased payer contracting pressure,
• and a spike in prescriber switching risk as at-risk launches approach.

Important constraint for this analysis. No Paragraph IV or ANDA litigation docket data is provided, so no challenger list can be produced.

---

What patent litigation and settlement agreements affect Actoplus Met XR launch timing?

Litigation mechanisms that influence financial trajectory.

• Automatic stay of FDA approval during litigation windows
• Design-around approvals that bypass certain claim coverage
• Consent judgments or “no further action” outcomes
• Licensing/authorized generic deals that may reduce brand revenue while keeping the brand “in the mix”

Important constraint for this analysis. No litigation docket or settlement terms are included in the input.

---

What formulations are protected for Actoplus Met XR (extended-release tablet vs alternatives)?

For extended-release fixed-dose products, the strongest commercial differentiators are often:

• tablet geometry and release kinetics,
• coating or matrix design,
• dissolution specifications,
• and manufacturing process parameters tied to release profile.

Commercial implication. If formulation protection is narrow or easily designable around, generic extended-release products can emerge quickly once regulatory barriers fall.

Important constraint for this analysis. No formulation patent coverage details are provided.

---

How does Actoplus Met XR compare with branded and generic alternatives in T2D combination therapy?

Relevant competitive substitutes.

• Separate metformin + pioglitazone products (generic-driven)
• Other fixed-dose metformin combinations (where payer preferences may shift)
• Newer SGLT2 and GLP-1 classes (often disrupt utilization even when metformin remains foundational)
• Other TZD-containing regimens depending on formulary rules

Competitive positioning impact.

• Actoplus Met XR’s market share is pressured by two substitution channels:
  1. cheaper generic metformin + pioglitazone,
  2. clinical and payer movement toward incretin-based and SGLT2-based regimens that can replace combinations earlier in treatment pathways.

---

What FDA pathway governs Actoplus Met XR today, and what does that mean for new competitors?

Generic entry pathway.

• For oral small molecules, competitors typically pursue ANDAs referencing approved listed drug (RLD) and submitting bioequivalence data.
• If patents are listed and Paragraph IV certifications are filed, court litigation can influence launch timing via statutory stays.

Commercial implication. Once a product is “open” to ANDA approvals without blocking patents, price compression usually follows quickly.

Important constraint for this analysis. The current FDA regulatory status (RLD references, listed strengths, and recent approvals) is not provided in the input.

---

What generic entry risks exist for Actoplus Met XR, and what launch scenarios are most likely?

Most likely launch scenarios.

• Launch of generic metformin + pioglitazone combination equivalents if fixed-dose ER patents are not enforceable or design-around is feasible.
• Launch of generic components separately if fixed-dose barrier blocks combination but component generics already dominate demand.
• Delayed competition via litigation stays, followed by stepwise market share erosion at lift of stays.

Financial impact pattern.

• Revenue typically declines in a non-linear step pattern: sales hold while barriers remain, then drop after the first at-risk/generic approvals, followed by continued erosion as pharmacies and payers switch to lowest-cost products.

---

What is the geographic coverage for Actoplus Met XR competition, and where is revenue most at risk?

U.S. is the core revenue market for most fixed-dose brand products, and patent litigation risk is U.S.-specific. Revenue risk concentrates in:

• the largest PBM-managed retail networks,
• Medicare Part D formularies,
• and state Medicaid preferred drug lists.

Important constraint for this analysis. No sales geography data is included in the input, so concentration by region cannot be quantified.

---

Key timeline framework: how Actoplus Met XR financials typically track exclusivity and entry

Below is a generic timeline structure for branded fixed-dose T2D products; specific dates must be filled from Orange Book and litigation records, which are not in the input.

Phase	Market event	Expected revenue trend	Primary driver
Phase 1	Brand launch and initial formulary adoption	Build/steady	Access and payer rebates
Phase 2	Limited competition	Plateau	Remaining exclusivity + limited substitutes
Phase 3	At-risk generic approvals approach	Flat to declining	Expectations shift, wholesalers adjust
Phase 4	First generic launch(s)	Step-down	Net price compression
Phase 5	Broader generic adoption	Continued erosion	Pharmacy switching and tiering

---

Key Takeaways

• Actoplus Met XR’s financial trajectory is structurally shaped by fixed-dose combination generic substitution risk and payer tiering in U.S. T2D formularies.
• Revenue pressure generally increases as ER formulation and fixed-dose patents lose enforceability or clear regulatory barriers.
• Newer T2D classes (SGLT2, GLP-1) intensify demand substitution risk even before generic entry.
• Specific exclusivity dates, Orange Book status, patent estate size, Paragraph IV challenges, litigation outcomes, and audited revenue trends cannot be stated from the provided input.

---

FAQs

1) What drives net price compression for metformin + pioglitazone combination products?
Rebate leverage, formulary tiering, and pharmacy benefit substitution to lower-cost generics of the components.

2) How does extended-release formulation protection change generic entry risk?
Broader, harder-to-design-around ER formulation patents can delay combination-generic approvals; narrow formulation claims tend to enable design-around.

3) What patterns should investors expect in branded T2D combination sales ahead of patent expiry?
Sales often flatten as market expectations shift, then decline in steps after the first generic launches and subsequent broad adoption.

4) Does litigation always prevent generic launches for fixed-dose ER products?
No. Statutory stays and settlements delay entry, but design-around and carve-outs can still enable earlier competition.

5) Why do fixed-dose combination brands lose share even when generics are not yet on shelf?
Payers can tighten coverage, requiring separate generic components or alternative regimens with better cost-effectiveness.

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
2. FDA. Drug Approval Reports and Related Information for ANDAs (general reference). U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda